Back

GOG 252

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma

Date of Publication:

April 19, 2019

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/31002578/
Hypothesis:

Does IP chemotherapy plus bevacizumab improves progression-free survival in women with optimally debulked ovarian cancer?

Control Arm(s):

Paclitaxel 80 mg/m2 weekly IV + carboplatin AUC 6 IV q3wks x6 cycles

bevacizumab 15 mg/kg IV starting cycle 2 + maintenance

Experimental Arm(s):

(1) Paclitaxel 80 mg/m2 weekly IV + carboplatin AUC 6 IP q3wks x6 cycles

bevacizumab 15 mg/kg IV starting cycle 2 + maintenance

(2) Paclitaxel 135 mg/m2 IV day 1 + cisplatin 75 mg/m2 IP day 2 + paclitaxel 60 mg/m2 IP day 8 q3wks x6 cycles

bevacizumab 15 mg/kg IV starting cycle 2 + maintenance

Primary End Point:

PFS

Inclusion Criteria:

stage II - IV epithelial ovarian cancer

Exclusion Criteria:
Results:

IP Carboplatin vs IP Cisplatin vs IV Carboplatin:

median f/u: 84.4 mos

median PFS: 27.4 vs 26.2 vs 24.9 months (NS)

median OS: 78.9 vs 72.9  vs 75.5 months (NS)

G3 adverse events: 17.2% vs 17.7% vs 11.5% (SS)

G3 HTN: 14% vs 20.5% vs 12%

G3 N/V: 5% va 11% vs 5%

No increases in bowel complications with IP chemo

Conclusions:

PFS was not increased with either IP cisplatin or IP carboplatin regimens when combined with bevacizumab as compared with IV carboplatin with bevacizumab for optimally debulked ovarian cancer.

Reviewer:
Mona Guo, OTF